Long-term Exercise Effect of EX1 Exercise Program

February 28, 2024 updated by: Yun-Hee Kim, Samsung Medical Center
The purpose of this study was to investigate the effect of a long-term exercise program using a wearable exoskeleton robot (EX1) on muscular strength in healthy adults aged 19 to under 65 years, compared to an exercise program without EX1.

Study Overview

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy adults aged 19 to less than 65 years without a history of central nervous system disease

Exclusion Criteria:

  • Those who have difficulty walking independently due to problems such as visual field defects or fractures
  • Those who have difficulty participating in exercise programs due to adult diseases such as uncontrolled hypertension and diabetes
  • Those who are at risk of falling while walking due to severe dizziness
  • Those who are less than 140 cm or more than 185 cm in height that is not suitable size for the wearing of the walking assistance robot
  • Those who are overweight based on body mass index (BMI) 35 or higher

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Overground walking exercise without EX1
Exercise consists of 30 minutes of overground walking.
Overground walking without EX1
Experimental: Exercise program 1 with EX1
Exercise program 1 consists of 30 minutes of overground walking.
EX1 is a hip-type assist device developed by Samsung Electronics.
Exercise program 1 for fast walking by applying resistance and assist mode of EX1
Experimental: Exercise program 2 with EX1
Exercise program 2 consists of 30 minutes of overground walking.
EX1 is a hip-type assist device developed by Samsung Electronics.
Exercise program 2 for normal walking by applying resistance and assist mode of EX1

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change on gait function (muscle activation)
Time Frame: Session 0 (initial visit); after session 18 (at approximately 6 weeks)
All subjects perform overground walking to assess the change of muscle activation after the interventions using a surface EMG (6 channels).
Session 0 (initial visit); after session 18 (at approximately 6 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in heart rate
Time Frame: Every session (total 18 sessions/ 30 minutes)
All subjects are measured for heart rate during the intervention.
Every session (total 18 sessions/ 30 minutes)
Reduction in stress level
Time Frame: Session 0 (initial visit); after session 18 (at approximately 6 weeks)

We evaluate the subject's usual stress level through a questionnaire. The Perceived Stress Scale (PSS-10) is a 10-item questionnaire originally developed by Cohen et al. (1983) widely used to assess stress levels in young people and adults.

The questions ask about feelings and thoughts during the last month. In each case, respondents are asked how often they felt a certain way on a five-point scale from 'never' to 'very often'. Answers are then scored as follow: Never = 0; Almost never = 1; Sometimes = 2; Fairly often = 3; Very often = 4.

The PSS score is then obtained by summing across all items. Higher scores indicate higher levels of perceived stress.

Session 0 (initial visit); after session 18 (at approximately 6 weeks)
Reduction in body fat percentage
Time Frame: Session 0 (initial visit); after session 18 (at approximately 6 weeks)
All subjects are measured for body fat before and after the intervention.
Session 0 (initial visit); after session 18 (at approximately 6 weeks)
User Satisfaction Questionnaire
Time Frame: After session 18 (at approximately 6 weeks)
We evaluate the satisfaction questionnaire for EX1 use and exercise program.
After session 18 (at approximately 6 weeks)
Change on gait function (kinematic)
Time Frame: Session 0 (initial visit); after session 18 (at approximately 6 weeks)
All subjects perform overground walking to assess the change of kinematic using a motion analysis.
Session 0 (initial visit); after session 18 (at approximately 6 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 28, 2023

Primary Completion (Actual)

September 30, 2023

Study Completion (Actual)

October 31, 2023

Study Registration Dates

First Submitted

March 22, 2023

First Submitted That Met QC Criteria

May 7, 2023

First Posted (Actual)

May 17, 2023

Study Record Updates

Last Update Posted (Actual)

February 29, 2024

Last Update Submitted That Met QC Criteria

February 28, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2023-03-005

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe